Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin-Reference-Cited by-同舟云学术

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

Published:2013-08-29 Issue:2 Volume:16 Page:159-169
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Bolinder J.¹,Ljunggren Ö.²,Johansson L.³⁴,Wilding J.⁵,Langkilde A. M.⁴,Sjöström C. D.⁴,Sugg J.⁶,Parikh S.⁶

Affiliation:

1. Department of Endocrinology, Metabolism and Diabetes; Karolinska University Hospital Huddinge, Karolinska Institute; Stockholm Sweden

2. Osteoporosis Research Unit, Department of Medical Sciences; Uppsala University; Uppsala Sweden

3. Department of Radiology, Oncology and Radiation Science (ROS), Section of Radiology; Uppsala University; Uppsala Sweden

4. AstraZeneca; Mölndal Sweden

5. Department of Obesity & Endocrinology; University of Liverpool; Liverpool UK

6. AstraZeneca; Wilmington DE USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12189/fullpdf

Reference26 articles.

1. Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus;Brunton;Postgrad Med,2012

2. Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs;Morgan;Diabetes Obes Metab,2012

3. Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes;Mudaliar;Diabetes Obes Metab,2010

4. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis;Loke;CMAJ,2009

5. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes;Meng;J Med Chem,2008

Cited by 396 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations;Diabetes, Obesity and Metabolism;2024-09-12

2. Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality;Diabetology & Metabolic Syndrome;2024-09-06

3. Impact of Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone Mineral Density in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis;International Journal of Molecular Sciences;2024-07-22

4. Bone Health in Patients With Type 2 Diabetes;Journal of the Endocrine Society;2024-05-23

5. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21